Please scroll down to bottom of email to add or remove your name from the IAS mailing list.

International Atherosclerosis
Society
e-Newsletter
January 2008

 


Back to IAS Home Page

www.athero.org




IAS AFFILIATIONS
International Chair on Cardiometabolic Risk
Metabolic Syndrome Institute
Society of Atherosclerosis Imaging and Prevention



IAS WEBSITE EDITORIAL BOARD
Editor-in-Chief
Scott M. Grundy, MD, PhD
Dallas, TX, USA
Associate Editors
Stefano Bellosta
Milan, Italy
Emanuela Folco
Milan, Italy
Ann Jackson
Houston, TX, USA
Website Editors
Gianpaolo Bagnato
Milan, Italy
Annamaria Scimone
Milan, Italy
Mandi Wong
Dallas, TX, USA

 

Featured IAS Commentaries

These Commentaries, including all information, text, graphics, images, and other material are for general educational purposes only and are not intended to be used for the purposes of providing medical treatment or attention or making medical or health-related decisions. These Commentaries are not a substitute or replacement for medical advice. If you are seeking medical advice, we encourage you to consult a physician or other medical professional. The views expressed in these Commentaries are those of the authors and are not necessarily those of IAS.

Inhibiting Vascular Inflammation with High Density Lipoproteins
Author: Kerry-Anne Rye

The high density lipoproteins (HDL) in human plasma comprise several subpopulations of spherical particles that are functionally diverse and vary widely in size and composition. Spherical HDL originate as discoidal particles that are secreted from the liver or assembled in the plasma from the individual constituents. The evidence that HDL protect against atherosclerosis is indisputable [1,2]. Population studies have shown that for every 1 mg/dL increase in HDL cholesterol levels, coronary heart disease risk decreases by 2-3% [3]. Of particular importance is a recent observation showing that this inverse relationship between HDL and coronary heart disease risk is still apparent, even when LDL levels are decreased to very low levels after treating with a statin [4]. When taken together, these findings emphasize the importance of understanding how HDL levels are regulated, determining whether all HDL subpopulations are equally cardioprotective, and identifying the mechanisms by which they protect against atherosclerosis.

> Read entire commentary


Metabolic Syndrome and Quality of Life
Authors: Andrea Corsonello, Francesco Corica, Giovanni Apolone and Giulio Marchesini

Acute cardiovascular events, such as stroke and myocardial infarction, have obvious consequences on quality of life (QoL) by limiting physical independence and affecting patients’ perception of psycho-social aspects pertaining health and life. Conversely, the impact of the metabolic syndrome (MS), a cluster of inter-related risk factors for accelerated atherosclerosis and cardiovascular disease [1], on QoL is less predictable and has not been clearly defined.

> Read entire commentary


Vascular Calcification in Chronic Kidney Disease Patients: An Emerging Problem with a Lot of Questions to Be Answered
Authors: Maria Eugênia F. Canziani, M.D., Ph.D. and Adriano Luiz Ammirati, M.D.

The burden of chronic kidney disease (CKD) has increased dramatically in recent decades, resulting in a greater number of patients requiring renal replacement therapy. Cardiovascular disease is the main cause of death in this population [1]. Vascular calcification (VC) is increasingly recognized as being a common complication at all stages of CKD [2,3]. Furthermore, the coronary artery calcification (CAC) is common and progressive in young adults with CKD who are beginning dialysis [4]. Recently, our group showed a high prevalence of CAC in pre-dialysis, peritoneal dialysis, and hemodialysis patients (49%, 59%, and 66%, respectively) [3,5,6] (Figure 1).

> Read entire commentary


Pulse Wave Velocity as a New Assessment Tool for Atherosclerosis
Authors: Hirohide Yokokawa, M.D., Ph.D., Aya Goto, M.D., MPH, Ph.D. and Seiji Yasumura, M.D., Ph.D.

The World Health Organization reported in 2005 that cardiovascular disease was the most
common cause of death worldwide, accounting for approximately 30% of all deaths [1].
Age-specific statistics show that the main cause of death between the ages of 15-59 was
HIV/AIDS, followed by ischemic heart disease and tuberculosis [2]. Among elderly individuals, main causes of death were ischemic heart disease followed by cerebrovascular disease [2]. The data stress the importance of preventing and treating atherosclerotic disease.

> Read entire commentary



Diabetes Mellitus, Metabolic Syndrome, Male Hypogonadism, and Erectile Dysfunction (by G. Corona, M. Maggi)
Authors: Giovanni Corona and Mario Maggi

Metabolic syndrome is a diagnostic category, based on a cluster of risk factors (hyperglycemia/diabetes, abdominal obesity, hypertriglyceridemia, low HDL cholesterol, and hypertension), which identifies subjects at high risk for forthcoming type 2 diabetes mellitus (T2DM) and cardiovascular (CV) diseases [1]. However, it should be recognized that MetS itself is a poor indicator of absolute short-term CV risk because it does not contain key determinants of short-term CV risk such as age, serum cholesterol, gender, and smoking status [1]. Accordingly, an attempt to use MetS for risk assessment to estimate for the short-term CV risk is a clear misuse of the syndrome [1]. On the other hand, the diagnosis of MetS in subjects at low-to-moderate CV risk should alert clinicians that such people deserve a more intensive lifestyle therapy at an early stage to delay progression to higher risk category [1].